Addressing Racial Disparities in Health Care
Treating Multiple Myeloma in the Second Line: Which Option Should You Choose?
After first-line multiple myeloma treatment, which strategy is best for second-line therapy?Learn More
Bispecific Antibodies Challenge CAR T-Cell Therapy as Multiple Myeloma Treatment Contender
The latest buzzword in multiple myeloma is bispecifics. This off-the-shelf treatment is proving to be an attractive option for patients who can't wait for CAR T-cell therapy.Learn More
Selinexor Worth Prescribing, with Proper Supportive Care
Prescribing the right dose of selinexor and navigating side effects have proved challenging in the treatment of patients with multiple myeloma.Learn More
How Do Two CAR T-Cell Therapies Stack Up When Comparing Results Across Trials?
Which of two investigational CAR T-cell therapies, vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), has the advantage?Learn More
Black Participation in Clinical Trials Is Imperative to Reduce Racial Disparities in Multiple Myeloma
By Kayle Waterhouse African Americans must be properly represented in clinical trials to ensure equal treatment for multiple myeloma and other cancers, top oncologists told SurvivorNet Connect. Dr. Ajay Nooka, a hematologist-oncologist at the Winship Cancer Institute, says Blacks are underrepresented in clinical trials. He states that “20% of the patients that we treat for […]Learn More
Why Oncologists Have to Take Time to Educate Themselves on the Broader Patient Population
By Kayle Waterhouse Too often oncologists forget about a significant portion of their patient population. As SurvivorNet Connect acknowledges racial disparities in multiple myeloma, a group of top oncologists noted that patient education requires an active approach from oncologists. Dr. Brandon Blue, a hematologist-oncologist at Moffitt Cancer Center, tells SurvivorNet Connect how important it is to recognize […]Learn More
The Evolution of Telemedicine – Considering Patients Who Don’t have WiFi
By Kayle Waterhouse As physicians adapt to a world in which connecting with patients over video has become a part of their day to day lives, there is significant debate about the effectiveness of telemedicine. In SurvivorNet’s virtual conference about reducing racial disparities in multiple myeloma, leading oncologists shared different views on telemedicine. “Unfortunately, not […]Learn More
Does Chemotherapy Still Have a Role in Frontline CLL Treatment?
In the past, the standard first-line therapy for chronic lymphocytic leukemia (CLL) was fludarabine-cyclophosphamide-rituximab (FCR). Because this regimen is both immunosuppressive and myelosuppressive, there has been a move away from FCR to novel combinations, such as venetoclax (brand name: Venclexta) plus obinutuzumab (brand name: Gazyva). Is there still a role for chemotherapy in the frontline treatment of CLL?Learn More